Excited to share that I will be joining @WeillCornell as an assistant professor. The Gabr lab will open its doors in January at the Molecular Imaging Innovations Institute @WCMRadiology We will use chemical biology and med chem to develop small molecule-based immunotheranostics

See how HICCC new member @MT_Gabr , a chemist by training, is bridging therapy and diagnostics to develop a new class of compounds in his lab that could both help visualize cancer and deliver treatment. Welcome to @ColumbiaMed Dr. Gabr and team! cancer.columbia.edu/news/mou…

🧬 This Week in OncoDaily IO: CAR-T Is Moving Beyond Its Traditional Boundaries oncodaily.com/oncolibrary/im… From solid tumors to diseases beyond oncology, CAR-T therapy is entering a new phase of innovation. 🟠 Stanley Niu — The expanding CAR-T landscape in China and access for international patients 🟠 @MT_Gabr— CAR-T beyond cancer, from autoimmune diseases to transplantation and fibrosis 🟠 Muhammad Shahid Mehmood — IL-18–armored CAR-T cells for immune-cold solid tumors 🟠 Snehal Gupta — The global CAR-T market and challenges in manufacturing, cost, reimbursement, and access 🟠 Fengqian Chen, PhD — Intracranial B7-H3 CAR-T therapy for recurrent glioblastoma 💡 Together, these perspectives highlight where CAR-T is heading next: smarter engineering, more precise delivery, broader applications, and greater accessibility.

Review @sigtrans_sttt @MT_Gabr @WeillCornell CAR T cell therapy beyond cancer: current status, challenges and future prospects nature.com/articles/s41392-0…

We're thrilled to announce that Moustafa Gabr, PhD, (@MT_Gabr), will join @columbiaimaging on July 1st as Director of Molecular Imaging and Therapeutics Research! #Theranostics #MolecularImaging #TeamScience #MolRad columbiaradiology.org/news/m…

In a fantastic collaboration with the group of @MT_Gabr, we have contributed to the discovery of a submicromolar agonist of TREM2, a new-generation Alzheimer's disease target. Read more in @ACSMedChemLett: pubs.acs.org/doi/10.1021/acs…

Designing immunity with cytokines: A logic-based framework for programmable CAR therapies sciencedirect.com/science/ar… @MT_Gabr @WeillCornell

HTS-Oracle: A Retrainable AI Platform for High-Confidence Hit Identification Across Difficult-to-Drug Targets 1. The introduction of HTS-Oracle marks a significant advancement in high-throughput screening (HTS) for drug discovery. This AI platform leverages deep learning to integrate molecular embeddings from ChemBERTa with traditional cheminformatics features, offering a powerful ensemble framework for predicting high-confidence hits across challenging targets. 2. One of the key innovations of HTS-Oracle is its ability to reprioritize and streamline the screening process. By enriching true positives and filtering out non-binders upfront, it significantly reduces the experimental burden and improves the efficiency of hit identification, particularly for difficult-to-drug targets like the immune co-stimulatory receptor CD28. 3. The platform demonstrated an impressive 8.4% hit rate in prospective screening, representing an eightfold improvement over conventional methods such as surface plasmon resonance (SPR) and affinity selection mass spectrometry (ASMS). This highlights HTS-Oracle’s potential to transform early-stage drug discovery by prioritizing high-confidence hits from large compound libraries. 4. HTS-Oracle’s architecture is designed for retrainability and adaptability. It can be retrained for new targets, making it a scalable and practical tool for iterative library refinement and target-specific optimization. This flexibility is crucial for addressing the diverse challenges in drug discovery across different therapeutic areas. 5. The study also validated the platform’s predictions experimentally, identifying two compounds that disrupted the CD28–B7.1 interaction with micromolar potency. These findings underscore the platform’s ability to identify novel small molecule inhibitors, even for targets historically considered intractable. 6. HTS-Oracle is released as an open-source platform, complete with training code and a pre-trained model. This accessibility encourages broader adoption and further development within the scientific community, providing a strong foundation for integrating AI into prospective screening workflows. 📜Paper: biorxiv.org/content/10.1101/… 💻Code: github.com/HTS-Oracle/CD28-p… #HTSOracle #AIDrugDiscovery #HighThroughputScreening #MachineLearning #DrugDiscovery #OpenSource #AIPlatform

🏥 Read "Virtual screening: hope, hype, and the fine line in between" by Hossam Nada, Nicholas Meanwell, & @MT_Gabr in 'Expert Opinion on Drug Discovery' 👉 tinyurl.com/c5ye4wbp

Excellent opportunity to join the Faltas lab

Our new paper published today in @Nature! Study Uncovers Mutations and DNA Structures Driving Bladder Cancer news.weill.cornell.edu/news/…

📝 Read "Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening," a @biorxivpreprint by Longfei Zhang, Laura Calvo-Barreiro, @MT_Gabr, & co. 👉 tinyurl.com/y4y3hnzb

🚨Job alert🚨Thrilled to share that the Gabr Lab received FIVE R01 grants for small molecule immunomodulators research. We are hiring postdocs with expertise in medicinal chemistry, neuropharmacology, or protein biochemistry. Applicants can send CVs to mog4005@med.cornell.edu

Happy to see our recent publication in ACS Medicinal Chemistry Letters highlighted on the journal cover! Details on this novel class of TIM-3-targeted peptides as immunomodulators can be found here: pubs.acs.org/doi/10.1021/acs…

🏥 Read "Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors," recent work from Somaya Abdel-Rahman & @MT_Gabr in @ACSMedChemLett, a publication of @AmerChemSociety, here 👉 tinyurl.com/bdfc4rh5

Glad to share that our paper on small molecule LAG-3 inhibitors has been selected for a special collection on the Future of Medicinal Chemistry. We’re proud to be the first to target LAG-3 with small molecules and thankful to the Elsa U. Pardee Foundation for their support

Introducing Genie 2, our latest protein design model! Genie 2 sets a new state of the art on key design metrics and supports motif scaffolding, including that of multiple motifs with undefined geometric relationships, a feature new to protein diffusion models. (1/5)

The Gabr Lab at Weill Cornell reports 3-oxo-lithocholic acid amidates as potent modulators of the nuclear receptor RORγt @MT_Gabr pubs.rsc.org/en/content/arti…

📝In 'Bioorganic & Medicinal Chemistry Letters,' the work of S. Abdel-Rahman, L. Calvo-Barreiro, & @MT_Gabr lays the groundwork for future #cancer drug discovery endeavors, with the goal of developing cyclic peptides targeting the ICOS/ICOSL interaction. sciencedirect.com/science/ar…

📢Read our Newly_Published_Paper "This comprehensive review explores cutting-edge developments in targeting immune #checkpoints, focusing on both #small_molecule- and #peptide-based approaches." 👨‍💻By Moustafa Gabr @MT_Gabr et al. 🏫@WeillCornell 📚More: mdpi.com/2626236

🧠 In @ACSChemNeurosci, a publication of @AmerChemSociety, @MT_Gabr reports new quinolinone hybrids as dual inhibitors of acetylcholinesterase (AChE) and Aβ aggregation, functioning as multitargeted ligands for Alzheimer's disease. pubs.acs.org/doi/10.1021/acs…